Journal of Immunotherapy · 2009 · 12 citations · 37 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCytokines In Tumor ImmunityDendritic Cell BiologyDendritic Cell RegulationOvarian CancerT Cell Responses To TumorsTumor Microenvironment ModulationCytokine MaturationImmunotherapy For Ovarian CancerOvarian Cancer ImmunologyOvarian Dendritic CellsPeripheral T Cell TolerancePeripheral Tolerance MechanismsTolerogenic Dendritic CellsTumor Microenvironment Effects
Local immunosuppressive mechanisms shape the tumor microenvironment and contribute to carcinogenesis. In ovarian cancer such mechanisms have been shown to influence survival. Dendritic cells (DCs) are central immunity regulators and induce potent cytotoxic T-cell responses as well as peripheral tolerance depending on modulatory stimuli. Here, we show that ovarian cancer-derived glycodelin (Gd), a glycoprotein that physiologically modulates local immunity in early pregnancy, induces a tolerogenic DC phenotype. Gd was isolated with high performance liquid chromatography from the malignant ascites of ovarian cancer patients. DCs were generated from monocytes of healthy donors and exposed to Gd with or without an inflammatory stimulus (tumor necrosis factor-alpha and interleukin 1-beta). We investigated the effect of Gd on DC surface marker expression, endopinocytotic activity, cytokine profile, and lymphoproliferative activity. DCs that were exposed to Gd altered their phenotype as seen by a differential expression of costimulatory molecules, whereas expression of DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, a marker of an immature phenotype, was increased. Functional data provided further evidence for the immature/tolerogenic properties of Gd-pretreated DCs. Antigen uptake was retained, production of interleukin-10 was increased, and lymphoproliferative activity was reduced. This effect was reversible by adding Gd-blocking antibodies. Gd, which is found in the malignant ascites of ovarian cancer patients, induces a tolerogenic phenotype in DC, thereby shaping an immunodeficient tumor micromilieu.
37
Federica Sallusto, Antonio Lanzavecchia · The Journal of Experimental Medicine · 1994 · 5.2K citations · Full text
Federica Sallusto, Marina Cella, Carlo Danieli et al. · The Journal of Experimental Medicine · 1995 · 2.5K citations · Full text
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
Tyler J. Curiel, Shuang Wei, Haidong Dong et al. · Nature Medicine · 2003 · 1.3K citations
Life Sciences, Immunology, Oncology +15